PTE - PolarityTE, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
13.63
-0.07 (-0.51%)
At close: 4:00PM EST

13.63 0.00 (0.00%)
After hours: 5:01PM EST

Stock chart is not supported by your current browser
Previous Close13.70
Open13.70
Bid13.45 x 1400
Ask16.54 x 1200
Day's Range13.48 - 14.38
52 Week Range11.54 - 1,340.21
Volume336,744
Avg. Volume230,345
Market Cap285.952M
Beta (3Y Monthly)1.94
PE Ratio (TTM)N/A
EPS (TTM)-4.86
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2016-01-12
1y Target Est43.75
Trade prices are not sourced from all markets
  • PolarityTE, Inc. (NASDAQ:PTE): The Best Of Both Worlds
    Simply Wall St.14 days ago

    PolarityTE, Inc. (NASDAQ:PTE): The Best Of Both Worlds

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Attractive stocks have exceptional fundamentals. In the Read More...

  • ACCESSWIRE19 days ago

    LD Micro Welcomes Nearly 1,000 Companies to the LD Micro Index

    LOS ANGELES, CA / ACCESSWIRE / February 1, 2019 / LD Micro is pleased to announce that the LD Micro Index is being reconstituted as of February 1, 2019. Again. We have always held the belief that our industry ...

  • Boswick Burn and Wound Symposium: New Data to be Presented on Preclinical and Clinical Use of SkinTE™
    PR Newswire19 days ago

    Boswick Burn and Wound Symposium: New Data to be Presented on Preclinical and Clinical Use of SkinTE™

    SALT LAKE CITY, Feb. 1, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE) announced today that new data on the preclinical and clinical use of its SkinTE™ product, a first-of-its-kind autologous, homologous human cellular and tissue-based product designed to regenerate full-thickness, functional skin for skin repair, reconstruction and replacement, will be presented at the 41st Annual Boswick Burn and Wound Symposium, February 2-7, 2019. PolarityTE is a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. One retrospective study of 13 patients treated for acute trauma, acute burns, burn reconstruction and chronic wounds, which failed or were refractory to the clinical standard of care, measures the effect of SkinTE treatment on wound closure, appendage development and ability to regenerate full-thickness skin, analogous to native skin.

  • PolarityTE Names Board Member David Seaburg as President of Corporate Development
    PR Newswire22 days ago

    PolarityTE Names Board Member David Seaburg as President of Corporate Development

    SALT LAKE CITY, Jan. 29, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE) announced today that David Seaburg will join the Company in the newly-created role of President of Corporate Development. PolarityTE is a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences.

  • Implied Volatility Surging for PolarityTE (PTE) Stock Options
    Zacks28 days ago

    Implied Volatility Surging for PolarityTE (PTE) Stock Options

    PolarityTE (PTE) needs investors to pay close attention to the stock based on moves in the options market lately.

  • World Stem Cell Summit: PolarityTE to Present Abstract on Regenerative Platform Technology
    PR Newswire28 days ago

    World Stem Cell Summit: PolarityTE to Present Abstract on Regenerative Platform Technology

    SALT LAKE CITY, Jan. 23, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE) announced today that it will present an abstract highlighting the PolarityTE platform technology at the Regenerative Medicine Foundation World Stem Cell Summit in Miami, Florida on January 24, 2019. PolarityTE is a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences.

  • PolarityTE Reports Fourth Quarter and Fiscal Year 2018 Results
    PR Newswirelast month

    PolarityTE Reports Fourth Quarter and Fiscal Year 2018 Results

    SALT LAKE CITY , Jan. 14, 2019 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, ...

  • PolarityTE Expands Contract Services Business with Addition of Jon Burrows
    PR Newswirelast month

    PolarityTE Expands Contract Services Business with Addition of Jon Burrows

    SALT LAKE CITY, Jan. 7, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences, today announced the appointment of Jon Burrows, PhD as President of Contract Services and Senior Vice President of Corporate Development. Dr. Burrows will oversee the market expansion of the Company's contract research organization (CRO) services, including that of its wholly-owned subsidiary, IBEX Preclinical Research, as well as corporate development efforts at large.

  • PolarityTE to Report Fiscal Fourth Quarter Financial Results on January 14, 2019
    PR Newswire2 months ago

    PolarityTE to Report Fiscal Fourth Quarter Financial Results on January 14, 2019

    SALT LAKE CITY, Jan. 3, 2019 /PRNewswire/ -- PolarityTE, Inc. (PTE), a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences, today announced that it will report its fiscal fourth quarter 2018 financial results by press release on January 14, 2019 at approximately 7:00 a.m. Eastern Time. In addition, the Company will host a conference call and webcast with Q&A on Wednesday, January 14, 2019 at 8:00 a.m. Eastern Time. The conference call can be accessed by calling 1-800-239-9838 (U.S. and Canada) or +44 (0)330 336 9105 (International), with the passcode 2482400 and referencing "PolarityTE 4th Quarter 2018 Earnings Call."  A webcast of the conference call can be accessed by using the link below.

  • PolarityTE Registers OsteoTE™ with U.S. Food and Drug Administration
    PR Newswire2 months ago

    PolarityTE Registers OsteoTE™ with U.S. Food and Drug Administration

    OsteoTE is a first-of-its-kind autologous (from the patient, for the patient) and homologous (bone for bone) product intended to repair, reconstruct, replace and supplement many types of bones using a small sample from the patient. In pre-clinical studies, OsteoTE demonstrated the capacity to regenerate bone with function and composition similar to natural bone. Pre-clinical animal studies suggest the product is a viable alternative to bone grafts and bone substitutes in treating long bone, craniomaxillofacial, spine, dental, hand and foot/ankle defects.

  • PolarityTE to Participate in Corporate Access Event in San Francisco, January 7-9, 2019
    PR Newswire2 months ago

    PolarityTE to Participate in Corporate Access Event in San Francisco, January 7-9, 2019

    SALT LAKE CITY, Dec. 27, 2018 /PRNewswire/ -- PolarityTE, Inc. (PTE), a commercial stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences, today announced that senior management will host institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event taking place in San Francisco, January 7-9, 2019. PolarityTE is a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences.

  • Investors Are Undervaluing PolarityTE, Inc. (NASDAQ:PTE) By 32.74%
    Simply Wall St.2 months ago

    Investors Are Undervaluing PolarityTE, Inc. (NASDAQ:PTE) By 32.74%

    Today I will be providing a simple run through of a valuation method used to estimate the attractiveness of PolarityTE, Inc. (NASDAQ:PTE) as an investment opportunity by taking the expected Read More...

  • PolarityTE and University Hospitals Cleveland Medical Center Announce System-Wide Approval of SkinTE™
    PR Newswire2 months ago

    PolarityTE and University Hospitals Cleveland Medical Center Announce System-Wide Approval of SkinTE™

    SALT LAKE CITY and CLEVELAND, Dec. 19, 2018 /PRNewswire/ -- PolarityTE, Inc. (PTE), a commercial-stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products using a patient's own tissue, and the University Hospitals Cleveland Medical Center jointly announced today that SkinTE™ is now available for use throughout the UH network of healthcare facilities. SkinTE is the first commercially-available autologous, homologous product that regenerates full-thickness skin that is fully-functional, and is an alternative to skin grafts and skin substitutes.

  • PolarityTE Announces Former FDA Official and Johnson & Johnson Executive Minnie Baylor-Henry Joins Board of Directors
    PR Newswire2 months ago

    PolarityTE Announces Former FDA Official and Johnson & Johnson Executive Minnie Baylor-Henry Joins Board of Directors

    SALT LAKE CITY, Dec. 11, 2018 /PRNewswire/ -- PolarityTE, Inc. (PTE), a commercial stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences, today announced the addition of Minnie Baylor-Henry to the Company's Board of Directors. Ms. Baylor-Henry is a regulatory affairs leader who served for nearly a decade at the U.S. Food and Drug Administration (FDA) before spending most of her career at Johnson & Johnson where she served in multiple roles, most recently as Worldwide Vice President of Regulatory Affairs.

  • PolarityTE to Present SkinTE Clinical Outcomes at Innovations in Wound Healing Conference
    PR Newswire3 months ago

    PolarityTE to Present SkinTE Clinical Outcomes at Innovations in Wound Healing Conference

    SALT LAKE CITY, Dec. 4, 2018 /PRNewswire/ -- PolarityTE, Inc. (PTE), a commercial stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences, announced today that it will present SkinTE™ clinical outcomes at the Innovations in Wound Healing Conference held in Key West, FL December 6-9, 2018. During a presentation entitled, Regeneration of Functional Skin, Stephen Milner, MD, DDS, DSc, FRCSE, FACS and Chief Clinical Officer of PolarityTE, who practiced medicine for more than 20 years and served as former Professor of Plastic and Reconstructive Surgery at the Johns Hopkins University School of Medicine and former Director of Johns Hopkins Burn Center, will discuss SkinTE clinical outcomes data.

  • PolarityTE Announces Recognition of SkinTE as Finalist for Fierce Innovation Awards Biotech Innovation
    PR Newswire3 months ago

    PolarityTE Announces Recognition of SkinTE as Finalist for Fierce Innovation Awards Biotech Innovation

    SALT LAKE CITY, Nov. 29, 2018 /PRNewswire/ -- PolarityTE, Inc. (PTE), a commercial stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences, announced today that its skin regeneration product, SkinTE™, has been named as a finalist in the Fierce Innovation Awards Life Science Edition 2018 in the Biotech Innovation category. Submissions are scored based on the following criteria: effectiveness, technical innovation, competitive advantage, financial impact and true innovation.

  • PolarityTE Announces Matt Kemp as Chief Commercial Officer
    PR Newswire3 months ago

    PolarityTE Announces Matt Kemp as Chief Commercial Officer

    SALT LAKE CITY, Nov. 27, 2018 /PRNewswire/ -- PolarityTE, Inc. (PTE), a commercial stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences, today announced the appointment of Matt Kemp as Chief Commercial Officer. Mr. Kemp will be integral in leading efforts as SkinTE™ moves toward a full national launch and in bringing other PolarityTE pipeline technologies and core "TE" products to market worldwide. With nearly 20 years of leadership experience, Mr. Kemp has an extensive record of driving profitable growth in both large and small biotech, medical device and pharmaceutical companies.

  • PolarityTE Receives Unique HCPCS Q-Code for SkinTE for Product Reimbursement from CMS
    PR Newswire3 months ago

    PolarityTE Receives Unique HCPCS Q-Code for SkinTE for Product Reimbursement from CMS

    SALT LAKE CITY, Nov. 21, 2018 /PRNewswire/ -- PolarityTE, Inc. (PTE), a commercial stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences, announced today that the Centers for Medicare and Medicaid (CMS) has assigned a unique product Q-code under the Healthcare Common Procedure Coding System (HCPCS) for SkinTE™.  This HCPCS Q-code will help facilitate the reimbursement for SkinTE. "Establishment of a unique Q-code is impactful to our reimbursement strategy to provide access for patients and providers to SkinTE.

  • PolarityTE to Participate in Piper Jaffray 30th Annual Healthcare Conference
    PR Newswire3 months ago

    PolarityTE to Participate in Piper Jaffray 30th Annual Healthcare Conference

    SALT LAKE CITY , Nov. 15, 2018 /PRNewswire/ --  PolarityTE, Inc. (Nasdaq: PTE), a commercial stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing ...

  • PolarityTE to Participate in Evercore ISI Healthcare Conference
    PR Newswire3 months ago

    PolarityTE to Participate in Evercore ISI Healthcare Conference

    SALT LAKE CITY, Nov. 14, 2018 /PRNewswire/ -- PolarityTE, Inc. (PTE), a commercial stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences, announced today that it will attend and present at the Evercore ISI Healthcare Conference held November 26-29, 2018 in Boston, MA. PolarityTE is a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences.

  • PolarityTE to Sponsor Epidermolysis Bullosa Research Partnership Event "ACTion for Jackson" in New York
    PR Newswire3 months ago

    PolarityTE to Sponsor Epidermolysis Bullosa Research Partnership Event "ACTion for Jackson" in New York

    SALT LAKE CITY, Nov. 7, 2018 /PRNewswire/ -- PolarityTE, Inc. (PTE), a commercial stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences, announced today that the Company will be the Title Sponsor for "ACTion for Jackson," a charitable event being held on November 8, 2018 in New York City, organized by the EB Research Partnership. During the event, Nikolai Sopko, MD, PhD, Chief Scientific Officer of PolarityTE will discuss the research PolarityTE is conducting in epidermolysis bullosa, a life-threatening rare genetic disease. PolarityTE's SkinTE™ product was used to treat an epidermolysis bullosa wound during the product's limited market release in early 2018, and the Company is currently using pre-clinical data to investigate genetically modifying SkinTE to develop treatments for epidermolysis bullosa and other genetic disorders.

  • PolarityTE® to Participate in the Canaccord Genuity Medical Technologies and Diagnostics Forum
    PR Newswire4 months ago

    PolarityTE® to Participate in the Canaccord Genuity Medical Technologies and Diagnostics Forum

    SALT LAKE CITY, Nov. 2, 2018 /PRNewswire/ -- PolarityTE, Inc. (PTE), a commercial stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences, announced today it will attend and present at the Canaccord Genuity Medical Technologies and Diagnostics Forum held November 15, 2018 in New York, NY. PolarityTE is a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences.

  • PolarityTE® Announces Presentation of SkinTE™ Clinical Outcomes at Symposium on Advanced Wound Care
    PR Newswire4 months ago

    PolarityTE® Announces Presentation of SkinTE™ Clinical Outcomes at Symposium on Advanced Wound Care

    The Symposium on Advanced Wound Care, which occurs each fall and spring, is a forum to connect the entire wound care team – physicians, nurses, physical therapists, researchers, scientists, podiatrists and dietitians – with the foremost experts in wound care to improve patient outcomes through education. There are expected to be more than 1,300 participants in attendance at the conference.

  • PolarityTE® Supports Development of Utah Biotech and Life Sciences Community
    PR Newswire4 months ago

    PolarityTE® Supports Development of Utah Biotech and Life Sciences Community

    SALT LAKE CITY, Oct. 29, 2018 /PRNewswire/ -- PolarityTE, Inc. (PTE), a commercial stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences, announced today its continued support of the Utah biotech and life sciences community through sponsorship and participation in the Utah Life Sciences Summit 2018, the premier event for Utah companies on the front lines of medical innovation, hosted by BioUtah on November 1, 2018 in Salt Lake City.